LONDON (Reuters) – The world’s first Ebola vaccine was approved by European drugs regulators on Friday in a move hailed by the World Health Organization (WHO) as a “triumph for public health” that would save many lives. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid The vaccine, developed by U.S. drugmaker Merck & Co, is already being used under emergency guidelines to try to protect people against the spread of a deadly Ebola outbreak in Democratic Republic of Congo. It is also being reviewed under a fast-track system by regulators in the United States. “This vaccine has already saved many lives in the current Ebola outbreak, and the decision by European regulator will help it to eventually save many more,” the WHO’s director-general Tedros Adhanom Ghebreyesus said in a statement. The Congo Ebola outbreak has killed more than 2,100 people since the middle of last year. It is the second largest Ebola outbreak in history, after a 2013-16 epidemic in West Africa that killed more than 11,300. The Merck vaccine, which the company has now brand-named Ervebo, is likely to get a… Read full this story
- Congo Ebola outbreak is 2nd largest, 2nd deadliest
- Who’s Irish Now?
- Raritan Valley Community College dance and music students set December performances
- Africa: New & Resurgent Infectious Diseases Can Have Far-Reaching Economic Repercussions
- Zimbabwe: Free Blood for Public, Mission Hospitals
- Brexit: How would no-deal affect Northern Ireland?
- Nigeria: Electricity Company Disconnects Imo Govt House Over N200 Million Debt
- Nigeria: Revealed
- David Davis resigns: How allies and rivals are reacting
- 'Escape at Dannemora' airs a terrifying flashback episode, just in time for Christmas
WHO hails 'triumph' as Merck's Ebola vaccine gets EU green light have 280 words, post on feeds.reuters.com at October 18, 2019. This is cached page on CuBird. If you want remove this page, please contact us.